FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1223-1232 March 27, 2003 Number 13 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Editorial by Foley, K. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Although opioids are commonly used to treat chronic neuropathic pain, there are limited data to guide their use. Few controlled trials have been performed, and many types of neuropathic pain remain unstudied.

Methods Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0.75-mg) or low-strength (0.15-mg) capsules of the potent µ-opioid agonist levorphanol for eight weeks under double-blind conditions. Intake was titrated by the patient to a maximum of 21 capsules of either strength per day. Outcome measures included the intensity of pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitive function, the number of capsules taken daily, and blood levorphanol levels.

Results Among the 81 patients exposed to the study drug, high-strength levorphanol capsules reduced pain by 36 percent, as compared with a 21 percent reduction in pain in the low-strength group (P=0.02). On average, patients in the high-strength group took 11.9 capsules per day (8.9 mg per day) and patients in the low-strength group took close to the 21 allowed (18.3 capsules per day; 2.7 mg per day). Affective distress and interference with functioning were reduced, and sleep was improved, but there were no differences between the high-strength group and the low-strength group in terms of these variables. Noncompletion of the study was primarily due to side effects of the opioid. Patients with central pain after stroke were the least likely to report benefit.

Conclusions The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses. Higher doses produced more side effects without significant additional benefit in terms of other outcome measures.

Source Information

From the Pain Clinical Research Center, Department of Neurology (M.C.R., L.T., P.S.D., L.R., K.T., D.M.), and the Department of Anesthesia (M.C.R.), University of California, San Francisco, School of Medicine; and the University of California, San Francisco, School of Pharmacy (L.R.) — all in San Francisco.

Address reprint requests to Dr. Rowbotham at the Pain Clinical Research Center, 1701 Divisadero St., Ste. 480, San Francisco, CA 94115.

Full Text of this Article

Related Letters:

Chronic Neuropathic Pain
Canavero S., Bonicalzi V., Simpson J. K. III, Foley K. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:2688-2689, Jun 26, 2003. Correspondence

This article has been cited by other articles:

• Kumar, B., Kalita, J., Kumar, G., Misra, U. K. (2009). Central Poststroke Pain: A Review of Pathophysiology and Treatment. Anesth. Analg. 108: 1645-1657 [Abstract] [Full Text]  
• Van Zee, A. (2009). The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy. AJPH 99: 221-227 [Abstract] [Full Text]  
• Jennings, M. B., Lesczczynski, C., Goodwin, S. (2008). The Safety and Efficacy of Pain Checker Socks in the Treatment of Mild-to-Moderate Foot Pain: A Clinical Trial. J. Am. Podiatr. Med. Assoc. 98: 278-282 [Abstract] [Full Text]  
• Galluzzi, K. E. (2007). Managing Neuropathic Pain. JAOA: Journal of the American Osteopathic Association 107: ES39-ES48 [Abstract] [Full Text]  
• Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 68: 515-521 [Abstract] [Full Text]  
• Lindgren, I., Jonsson, A.-C., Norrving, B., Lindgren, A. (2007). Shoulder Pain After Stroke: A Prospective Population-Based Study. Stroke 38: 343-348 [Abstract] [Full Text]  
• Porreca, F., Vanderah, T. W., Guo, W., Barth, M., Dodey, P., Peyrou, V., Luccarini, J. M., Junien, J.-L., Pruneau, D. (2006). . J. Pharmacol. Exp. Ther. 318: 195-205 [Abstract] [Full Text]  
• Somers, D. L, Clemente, F R. (2006). Transcutaneous Electrical Nerve Stimulation for the Management of Neuropathic Pain: The Effects of Frequency and Electrode Position on Prevention of Allodynia in a Rat Model of Complex Regional Pain Syndrome Type II. ptjournal 86: 698-709 [Abstract] [Full Text]  
• Sinatra, R. (2006). Opioid Analgesics in Primary Care: Challenges and New Advances in the Management of Noncancer Pain. J Am Board Fam Med 19: 165-177 [Abstract] [Full Text]  
• Rowbotham, M. C. (2005). Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 65: S66-S73 [Abstract] [Full Text]  
• Wu, H.-E., Thompson, J., Sun, H.-S., Terashvili, M., Tseng, L. F. (2005). Antianalgesia: Stereoselective Action of dextro-Morphine over levo-Morphine on Glia in the Mouse Spinal Cord. J. Pharmacol. Exp. Ther. 314: 1101-1108 [Abstract] [Full Text]  
• Galluzzi, K. E. (2005). Management of Neuropathic Pain. JAOA: Journal of the American Osteopathic Association 105: S12-S19 [Abstract] [Full Text]  
• Eisenberg, E., McNicol, E. D., Carr, D. B. (2005). Efficacy and Safety of Opioid Agonists in the Treatment of Neuropathic Pain of Nonmalignant Origin: Systematic Review and Meta-analysis of Randomized Controlled Trials. JAMA 293: 3043-3052 [Abstract] [Full Text]  
• Buntin-Mushock, C., Phillip, L., Moriyama, K., Palmer, P. P. (2005). Age-Dependent Opioid Escalation in Chronic Pain Patients. Anesth. Analg. 100: 1740-1745 [Abstract] [Full Text]  
• Likar, R., Sittl, R. (2005). Transdermal Buprenorphine for Treating Nociceptive and Neuropathic Pain: Four Case Studies. Anesth. Analg. 100: 781-785 [Abstract] [Full Text]  
• Rubey, R. N. (2005). Treatment of chronic pain in persons with dementia: An overview. AM J ALZHEIMERS DIS OTHER DEMEN 20: 12-20 [Abstract]  
• Chen, H., Lamer, T. J., Rho, R. H., Marshall, K. A., Sitzman, B. T., Ghazi, S. M., Brewer, R. P. (2004). Contemporary Management of Neuropathic Pain for the Primary Care Physician. Mayo Clin Proc. 79: 1533-1545 [Abstract]  
• Ji, R.-R., Strichartz, G. (2004). Cell Signaling and the Genesis of Neuropathic Pain. Sci Signal 2004: re14-re14 [Abstract] [Full Text]  
• Lussier, D., Huskey, A. G., Portenoy, R. K. (2004). Adjuvant Analgesics in Cancer Pain Management. The Oncologist 9: 571-591 [Abstract] [Full Text]  
• Ballantyne, J. C. (2003). Chronic Pain Following Treatment for Cancer: The Role of Opioids. The Oncologist 8: 567-575 [Abstract] [Full Text]  
• Ballantyne, J. C., Mao, J. (2003). Opioid Therapy for Chronic Pain. NEJM 349: 1943-1953 [Full Text]  
• Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., Bushnell, M. C., Farrar, J. T., Galer, B. S., Haythornthwaite, J. A., Hewitt, D. J., Loeser, J. D., Max, M. B., Saltarelli, M., Schmader, K. E., Stein, C., Thompson, D., Turk, D. C., Wallace, M. S., Watkins, L. R., Weinstein, S. M. (2003). Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations. Arch Neurol 60: 1524-1534 [Abstract] [Full Text]  
• Canavero, S., Bonicalzi, V., Simpson, J. K. III, Foley, K. M. (2003). Chronic Neuropathic Pain. NEJM 348: 2688-2689 [Full Text]  
• (2003). Opioids for Neuropathic Pain. JWatch Psychiatry 2003: 8-8 [Full Text]  
• Enck, R. E. (2003). Neuropathic pain. AM J HOSP PALLIAT CARE 20: 171-172  
• (2003). Opioids for Neuropathic Pain. JWatch General 2003: 2-2 [Full Text]  
• Mendell, J. R., Sahenk, Z. (2003). Painful Sensory Neuropathy. NEJM 348: 1243-1255 [Full Text]  
• Foley, K. M. (2003). Opioids and Chronic Neuropathic Pain. NEJM 348: 1279-1281 [Full Text]